USPTO serial 79236788
INNOPHLEX
Reviewed by CopyMark Law Group
Reg. 5893636Status 709
- Filing date
- Status date
- Registration date
- Oct 29, 2019
- Examiner
- PODESTA, GIDETTE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with INNOPHLEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Friedrichsdorf, DE
Friedrichsdorf, DE
Friedrichsdorf, DE
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Advertising services, business management for others, company administration in the nature of business administration services; providing office functions; business efficiency expert services; systemization of information into computer databases; compilation of information into computer databases; business assistance and consultancy in the context of the retailing and wholesaling of medicines; providing of outsourcing services in the field of business management for companies engaged in the field of medicine authorization, production, sale, safety and monitoring; regulatory submission management, namely, filing of documents for authorizing medicines using documents, reports and files required by regulatory authorities; administrative assistance and consultancy in the nature of preparation and filing of applications for pharmaceutical medicine approval with governmental regulatory bodies | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, scientific research, laboratory research in the field of pharmaceuticals; industrial analysis and research services, namely, laboratory research services relating to pharmaceuticals, pharmaceutical research services; research and development of new products for others; provision of surveys, namely, medical research surveys; software development services, namely, development of a web application for inputting and using informative texts for medicines and medical products, in particular user guides, packaging inserts, specialist information, and for providing various documents; database services, namely, electronic storage of data in computer databases; conversion of data or documents from physical to electronic media; research in relation to scientific work; preparation of scientific analysis and assessments; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing; pharmaceutical products development; development of pharmaceutical preparations and medicines; testing of pharmaceuticals; provision of information and data relating to medical and veterinary research and development; inspection of pharmaceuticals; scientific investigations for medical purposes; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical drug development services; medical laboratory services; information technology advisory, consultancy and information services for the pharmaceutical and healthcare industries; scientific assessment of the efficiency of medicines; services for assessing the efficiency of pharmaceuticals being pharmaceutical product evaluation; analysis and evaluation of product design; analysis and evaluation of product development; quality control testing for others; materials testing and evaluation; product safety testing; quality control services, namely, testing, analysis and evaluation of the services of others to determine conformity with certification standards; quality testing of products for certification purposes; assistance and consultancy in the nature of pharmaceutical research in the field of medicine safety and monitoring; pharmaceutical drug development consultancy in the field of medicine safety | SECTION 71 - CANCELLED | — |
| 044 | Providing pharmaceutical and medical assistance and consultancy during an initial application process of marketing authorization or product approval for pharmaceutical companies; provision of medical and pharmaceutical advice and expertise for pharmaceutical companies; providing information relating to the preparation and dispensing of medications; provision of pharmaceutical information; provision of information relating to medicine; consultancy and information services provided via the internet relating to pharmaceutical products; consultancy and information services relating to pharmaceutical products; consultancy and information services relating to biopharmaceutical products; advisory services relating to pharmaceuticals; medical services, medical diagnostic services; medical services, medical diagnostic services and pharmaceutical advisory services and consultancy in the field of medicine safety | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PharmaLex GmbH
- Other trademarks owned by PharmaLex GmbH
- Other trademarks owned by PharmaLex GmbH
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INNOPHLEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 15, 2026 | C71T | CANCELLED SECTION 71 | — |
| Nov 15, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 29, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 18, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 21, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 6, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 19, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 19, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 29, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 29, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 13, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 13, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 9, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 24, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 24, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 24, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 9, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 8, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 8, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 8, 2019 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 15, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 15, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 15, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 22, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 22, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 22, 2018 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 22, 2018 | ALIE | ASSIGNED TO LIE | — |
| Dec 19, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 19, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 1, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 13, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 13, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 31, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 30, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 27, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 23, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 23, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 19, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |